Exact Sciences stock crashed Wednesday after the company inked a deal for the exclusive eights to Freenome's blood-based ...

Easy at-home tests for colon cancer, including FIT and Cologuard, offer alternatives to traditional colonoscopies for early detection and prevention.

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue ...

Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Cologuard is easy for patients to use and easy for doctors to interpret the results, said Dr. Casey Allen, a surgical oncologist at Allegheny Health Network in Pennsylvania.

The Cologuard test is not a replacement for colonoscopy in high risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older.

The Cologuard test is not a replacement for colonoscopy in high risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older.

Cologuard measures DNA methylation in two genes: NDRG4 and BMP3. Abnormal methylation of NDRG4 and BMP3, considered tumor suppressors, has been linked to colorectal tumors.

The 2024 Cologuard Classic will be played at La Paloma Country Club for the first time. Despite the venue change, the tournament's mission remains the same.

Outside of those patients, Cologuard will own its addressable market and be rapidly adopted by physicians. Eventual penetration into the 70% range of this market is reasonable, and even at $300 ...